The reduction of superoxide dismutase activity is associated with the severity of neurological soft signs in patients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 52-56

  Raffa, Monia ^a   Fendri, Chiraz ^b   Ben Othmen, Leila ^a   Slama, Héla ^b   Amri, Montassar ^b   Kerkeni, Abdelhamid ^a   Mechri, Anwar ^b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b Teaching Hospital of Monastir   (Tunisia)

Author keywords

Antioxidant enzymes; Neurodevelopment; Neurological soft signs; Oxidative stress; Schizophrenia

Indexed keywords

CATALASE; GLUTATHIONE PEROXIDASE; NEUROLEPTIC AGENT; SUPEROXIDE DISMUTASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR COORDINATION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; OXIDATIVE STRESS; SCHIZOPHRENIA; SCORING SYSTEM; SENSORIMOTOR INTEGRATION;

ADULT; CASE-CONTROL STUDIES; CATALASE; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; NEUROLOGIC EXAMINATION; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE;

EID: 84864511271     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.005     Document Type: Article

References (54)

1. Akyol O., Herken H., Uz E., Fadillioǧlu E., Unal S., Söǧüt S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26(5):995-1005.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
3. Atkins M., Burgess A., Bottomley C., Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull 1997, 21:224-226.
4. Ben Othmen L., Mechri A., Fendri C., Bost M., Chazot G., Gaha L., et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(1):155-159.
5. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35(3):878-893.
6. Bombin I., Arango C., Buchanan R.W. Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull 2005, 31(4):962-977.
7. Bošković M., Vovk T., Kores Plesničar B., Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9(2):301-312.
8. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 1990, 31(1):1-14.
9. Aebi H. Catalase. Methods of enzymatic analysis 1974, 673-677. Academic Press, New York and London.
10. Chan R.C., Gottesman I.I. Neurological soft signs as candidate endophenotypes for schizophrenia: a shooting star or a Northern star?. Neurosci Biobehav Rev 2008, 32(5):957-971.
11. Chan R.C., Xu T., Heinrichs R.W., Yu Y., Wang Y. Neurological soft signs in schizophrenia: a meta-analysis. Schizophr Bull 2010, 36(6):1089-1104.
12. Dadheech G., Mishra S., Gautam S., Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008, 50:16-20.
13. Das M., Kumari V., Soni W., Ettinger U., Binneman B., Hughes C., et al. Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia. Schizophr Bull 2004, 30(2):241-253.
14. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009, 19(2):220-230.
15. Fendri C., Mechri A., Khiari G., Othman A., Kerkeni A., Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encéphale 2006, 32:244-252.
16. Gunzler W.A., Kremers H., Flohe L. An improved coupled test procedure for glutathione peroxidase in blood. Z Klin Biochem 1974, 12:444-448.
17. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10(1):40-68.
18. Hitzeroth A., Niehaus D.J., Koen L., Botes W.C., Deleuze J.F., Warnich L. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(3):664-672.
19. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998, 30(3):193-208.
20. John J.P. Fronto-temporal dysfunction in schizophrenia: a selective review. Indian J Psychiatry 2009, 51(3):180-190.
21. Kang S.G., Choi J.E., An H., Park Y.M., Lee H.J., Han C., et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(8):1844-1847.
22. Keshavan M.S., Sanders R.D., Sweeney J.A., Diwadkar V.A., Goldstein G., Pettegrew J.W., et al. Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses. Am J Psychiatry 2003, 160(7):1298-1304.
23. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58(1):1-10.
24. Krebs M.O., Mouchet S. Neurological soft signs and schizophrenia: a review of current knowledge. Rev Neurol 2007, 163(12):1157-1168.
25. Krebs M.O., Gut-Fayand A., Bourdel M., Dischamp J., Olié J. Validation and factorial structure of a standardized neurological examination assessing neurological soft signs in schizophrenia. Schizophr Res 2000, 45(3):245-260.
26. Liu H., Wang C., Chen P.H., Zhang B.S., Zheng Y.L., Zhang C.X., et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(4):692-696.
27. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17(1):47-62.
28. Lynn S., Huang E.J., Elchuri S., Naeemuddin M., Nishinaka Y., Yodoi J., et al. Selective neuronal vulnerability and inadequate stress response in superoxide dismutase mutant mice. Free Radic Biol Med 2005, 38(6):817-828.
29. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996, 19(1):1-17.
30. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25(3):463-493.
31. Mahadik S.P., Pillai A., Joshi S., Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 2006, 18(2):119-131.
32. Markund S., Markund G. Involvement of the superoxide anion radical in autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974, 47:469-474.
33. Mechri A., Bourdel M.C., Slama H., Gourion D., Gaha L., Krebs M.O. Neurological soft signs in patients with schizophrenia and their unaffected siblings: frequency and correlates in two ethnic and socioeconomic distinct populations. Eur Arch Psychiatry Clin Neurosci 2009, 259(4):218-226.
34. Nakajima S., Ohsawa I., Nagata K., Ohta S., Ohno M., Ijichi T., et al. Oral supplementation with melon superoxide dismutase extract promotes antioxidant defences in the brain and prevents stress-induced impairment of spatial memory. Behav Brain Res 2009, 200(1):15-21.
35. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11(6):851-876.
36. Pae C.U., Kim T.S., Patkar A.A., Kim J.J., Lee C.U., Lee S.J., et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. Psychiatry Res 2007, 153(1):77-81.
37. Perry S.W., Norman J.P., Litzburg A., Gelbard H.A. Antioxidants are required during the early critical period, but not later, for neuronal survival. J Neurosci Res 2004, 78(4):485-492.
38. Picard H.J., Amado I., Bourdel M.C., Landgraf S., Olié J.P., Krebs M.O. Correlates between neurological soft signs and saccadic parameters in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(4):676-681.
39. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(7):1178-1183.
40. Raffa M., Atig F., Mhalla A., Kerkeni A., Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11:124.
41. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121(2):109-122.
42. Scheffer R., Mahadik S.P., Carrenti E.E., Mc Clure M., Mukherjee S. Membrane lipid peroxidation and neurological signs in first episode psychosis. Biol Psychiatry 1995, 37(9):681.
43. Simpson G.M., Angus J.W.S. A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 1970, 212:11-19.
44. SPSS 10.0 Statistical Package for the Social Sciences (SPSS) for Windows, version 10.0 1994, SPSS Inc., Chicago, IL.
45. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000, 47(3):210-220.
46. Venkatasubramanian G., Latha V., Gangadhar B.N., Janakiramaiah N., Subbakrishna D.K., Jayakumar P.N., et al. Neurological soft signs in never-treated schizophrenia. Acta Psychiatr Scand 2003, 108(2):144-146.
47. Yao J.K., van Kammen D.P. Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol 2004, 59:297-326.
48. Yao J.K., Reddy R.D., Van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15(4):287-310.
49. Yoo D.Y., Shin B.N., Kim I.H., Kim W., Kim D.W., Yoo K.Y., et al. Effects of Cu, Zn-superoxide dismutase on cell proliferation and neuroblast differentiation in the mouse dentate gyrus. Neurochem Res 2012, 37(2):261-267.
50. Zai C.C., Tiwari A.K., Basile V., de Luca V., Müller D.J., Voineskos A.N., et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(1):50-56.
51. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2003, 62(3):245-250.
52. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300.
53. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., et al. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 2007, 68(5):754-760.
54. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010, 53:112-124.